

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1.-62. (Canceled).

63. (New) An antibody or fragment thereof that binds to human mannose binding lectin (MBL), comprising:

a CDR3 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

64. (New) The antibody or fragment thereof of claim 63, wherein the CDR3 is a heavy chain CDR3.

65. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof comprises a CDR3 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.

66. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof comprises a CDR3 of a monoclonal antibody produced by hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.

67. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof comprises a CDR3 of a monoclonal antibody produced by hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

68. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof is a monoclonal antibody.

69. (New) The antibody or fragment thereof of claim 68, wherein the monoclonal antibody is produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.

70. (New) The antibody or fragment thereof of claim 68, wherein the monoclonal antibody is produced by hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.

71. (New) The antibody or fragment thereof of claim 68, wherein the monoclonal antibody is produced by hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

72. (New) The antibody or fragment thereof of claim 68, wherein the monoclonal antibody is a humanized monoclonal antibody.

73. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof is a single chain antibody.

74. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof is an F(ab')₂ fragment, an Fab fragment, an Fv fragment, or an Fd fragment.

75. (New) The antibody or fragment thereof of claim 63, further comprising:
a CDR2 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

76. (New) The antibody or fragment thereof of claim 75, wherein the CDR2 is a light chain CDR2.

77. (New) The antibody or fragment thereof of claim 63, further comprising:
a CDR1 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

78. (New) The antibody or fragment thereof of claim 77, wherein the CDR1 is a light chain CDR1.

79. (New) The antibody or fragment thereof of claim 77, further comprising:
a CDR2 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

80. (New) A hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.

81. (New) A hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.

82. (New) A hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

83. (New) A composition comprising:
the antibody or fragment thereof of claim 63 and a pharmaceutically acceptable carrier.

84. (New) The composition of claim 83, wherein the antibody or fragment thereof is in an amount effective to treat an MBL mediated disorder.

85. (New) The composition of claim 83, further comprising a drug for the treatment of an MBL mediated disorder.